Don't miss

Replay


LATEST SHOWS

THE INTERVIEW

President Ellen Johnson Sirleaf hails 'milestone' as UN peacekeepers leave Liberia

Read more

IN THE PAPERS

The 'Brexecution' of Boris Johnson

Read more

IN THE PAPERS

State of British Politics 'Worse than Shakespeare'

Read more

PEOPLE & PROFIT

From London to Abu Dhabi: How Brexit sent shockwaves across the world

Read more

BUSINESS DAILY

Carney: UK suffering from 'economic post-traumatic stress'

Read more

ACROSS AFRICA

Liberia UNMIL mission: Peacekeepers prepare to hand over to government

Read more

MEDIAWATCH

Boris Backs Out After Brexit

Read more

EYE ON AFRICA

DRC elections: Kabila says poll will go ahead

Read more

THE DEBATE

Chaos at Westminster: UK's post-Brexit leadership battle (part 1)

Read more

SCIENCE

Swiss drugs giant Roche donates anti-viral treatments

Latest update : 2009-05-12

Swiss drugs manufacturer Roche said it is donating 5.65 million treatment courses of its anti-viral drug Tamiflu to help fight the worldwide outbreak of the Influenza A (H1N1) virus.

AFP - Swiss drugs giant Roche said Tuesday it was donating 5.65 million treatment courses of its anti-viral drug Tamiflu to help the World Health Organisation fight the swine flu outbreak.
  
It added in a statement that it would also boost its production capacity for anti-virals, producing another 110 million treatment courses over the next five months.
  
Following that, it would further ramp up capacity to a maximum output of 36 million treatments per month by year-end if required.
  
"The recent outbreak of influenza A(H1N1) shows that such a virus can be totally unexpected and spread rapidly around the globe," said William Burns, CEO of Roche's pharmaceuticals division.
  
The outbreak "emphasises the urgency" of replenishing the stockpiles to prepare for subsequent waves of the virus, he added.
  
Roche said its latest donation would help replenish stockpiles of the UN health agency which have been deployed to deal with the current outbreak.
  
Two million courses of the drug will be held by the WHO, while three million courses will be held by Roche on behalf of the organisation.
  
The remaining 650,000 treatment courses of smaller Tamiflu capsules will form a new pediatric stockpile, said the group.
  
"In view of the uncertain impact of the influenza A(H1N1) virus on the current Southern Hemisphere influenza season, and the subsequent Northern Hemisphere winter season, it will be important for all stakeholders to closely monitor events and continue pandemic preparedness," added Roche.
  
Thirty countries have reported 4,694 laboratory confirmed cases of influenza A(H1N1), including 53 deaths, to the WHO.

Date created : 2009-05-12

COMMENT(S)